The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration
Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public–private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2010-05, Vol.87 (5), p.539-542 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 542 |
|---|---|
| container_issue | 5 |
| container_start_page | 539 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 87 |
| creator | Wagner, J A Prince, M Wright, E C Ennis, M M Kochan, J Nunez, D J R Schneider, B Wang, M‐D Chen, Y Ghosh, S Musser, B J Vassileva, M T |
| description | Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public–private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator–activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross‐company precompetitive collaboration is a feasible robust approach to biomarker qualification.
Clinical Pharmacology & Therapeutics (2010) 87 5, 539–542. doi: 10.1038/clpt.2009.227 |
| doi_str_mv | 10.1038/clpt.2009.227 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733592570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733592570</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3727-95e36ca80915ff98fa0b6b8f080efc5360db7108893b169da6259f9beecc66353</originalsourceid><addsrcrecordid>eNp9kMFu1DAQhi1ERbeFI1eUC-opi2PHjt0bjSggrdRIXa5YjncsTJM42ElRbzwCz9gnqaPdtreerPF8_mf8IfS-wOsCU_HJdOO0JhjLNSHVK7QqGCU5Z5S9RiucrnNJKD9GJzH-TmUphXiDjgkucVVyvEI_t78gu3C-1-EGQsxqP0QfJjf351kTtJmcgUwPu6xxk9VdFzNvs6sRhvt__6_9HFK3CWB8P8LkJncLKaHrdOuDnpwf3qKj9CrCu8N5in5cftnW3_LN1dfv9edNbmhFqlwyoNxogWXBrJXCatzyVlgsMFjDKMe7tiqwEJK2BZc7zQmTVrYAxnBOGT1FZ_vcMfg_M8RJ9S4aSJsM4OeoKkqZJKzCicz3pAk-xgBWjcGl39-pAqvFqFqMqsWoSkYT_-GQPLc97J7oR4UJ-HgAdDS6s0EPxsVnjlRlSYslSO65v66Du5enqrrZ1ptmu9TLEg9vBJH7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733592570</pqid></control><display><type>article</type><title>The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wagner, J A ; Prince, M ; Wright, E C ; Ennis, M M ; Kochan, J ; Nunez, D J R ; Schneider, B ; Wang, M‐D ; Chen, Y ; Ghosh, S ; Musser, B J ; Vassileva, M T</creator><creatorcontrib>Wagner, J A ; Prince, M ; Wright, E C ; Ennis, M M ; Kochan, J ; Nunez, D J R ; Schneider, B ; Wang, M‐D ; Chen, Y ; Ghosh, S ; Musser, B J ; Vassileva, M T</creatorcontrib><description>Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public–private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator–activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross‐company precompetitive collaboration is a feasible robust approach to biomarker qualification.
Clinical Pharmacology & Therapeutics (2010) 87 5, 539–542. doi: 10.1038/clpt.2009.227</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2009.227</identifier><identifier>PMID: 20407460</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Animals ; Biological and medical sciences ; Biomarkers - metabolism ; Cooperative Behavior ; Drug Delivery Systems - methods ; Drug Delivery Systems - trends ; Drug Design ; Drug Industry - economics ; Drug Industry - methods ; Drug Industry - trends ; Economic Competition - economics ; Economic Competition - trends ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic - trends</subject><ispartof>Clinical pharmacology and therapeutics, 2010-05, Vol.87 (5), p.539-542</ispartof><rights>2010 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3727-95e36ca80915ff98fa0b6b8f080efc5360db7108893b169da6259f9beecc66353</citedby><cites>FETCH-LOGICAL-c3727-95e36ca80915ff98fa0b6b8f080efc5360db7108893b169da6259f9beecc66353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2009.227$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2009.227$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22744317$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20407460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wagner, J A</creatorcontrib><creatorcontrib>Prince, M</creatorcontrib><creatorcontrib>Wright, E C</creatorcontrib><creatorcontrib>Ennis, M M</creatorcontrib><creatorcontrib>Kochan, J</creatorcontrib><creatorcontrib>Nunez, D J R</creatorcontrib><creatorcontrib>Schneider, B</creatorcontrib><creatorcontrib>Wang, M‐D</creatorcontrib><creatorcontrib>Chen, Y</creatorcontrib><creatorcontrib>Ghosh, S</creatorcontrib><creatorcontrib>Musser, B J</creatorcontrib><creatorcontrib>Vassileva, M T</creatorcontrib><title>The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public–private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator–activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross‐company precompetitive collaboration is a feasible robust approach to biomarker qualification.
Clinical Pharmacology & Therapeutics (2010) 87 5, 539–542. doi: 10.1038/clpt.2009.227</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - metabolism</subject><subject>Cooperative Behavior</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Delivery Systems - trends</subject><subject>Drug Design</subject><subject>Drug Industry - economics</subject><subject>Drug Industry - methods</subject><subject>Drug Industry - trends</subject><subject>Economic Competition - economics</subject><subject>Economic Competition - trends</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic - trends</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu1DAQhi1ERbeFI1eUC-opi2PHjt0bjSggrdRIXa5YjncsTJM42ElRbzwCz9gnqaPdtreerPF8_mf8IfS-wOsCU_HJdOO0JhjLNSHVK7QqGCU5Z5S9RiucrnNJKD9GJzH-TmUphXiDjgkucVVyvEI_t78gu3C-1-EGQsxqP0QfJjf351kTtJmcgUwPu6xxk9VdFzNvs6sRhvt__6_9HFK3CWB8P8LkJncLKaHrdOuDnpwf3qKj9CrCu8N5in5cftnW3_LN1dfv9edNbmhFqlwyoNxogWXBrJXCatzyVlgsMFjDKMe7tiqwEJK2BZc7zQmTVrYAxnBOGT1FZ_vcMfg_M8RJ9S4aSJsM4OeoKkqZJKzCicz3pAk-xgBWjcGl39-pAqvFqFqMqsWoSkYT_-GQPLc97J7oR4UJ-HgAdDS6s0EPxsVnjlRlSYslSO65v66Du5enqrrZ1ptmu9TLEg9vBJH7</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Wagner, J A</creator><creator>Prince, M</creator><creator>Wright, E C</creator><creator>Ennis, M M</creator><creator>Kochan, J</creator><creator>Nunez, D J R</creator><creator>Schneider, B</creator><creator>Wang, M‐D</creator><creator>Chen, Y</creator><creator>Ghosh, S</creator><creator>Musser, B J</creator><creator>Vassileva, M T</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201005</creationdate><title>The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration</title><author>Wagner, J A ; Prince, M ; Wright, E C ; Ennis, M M ; Kochan, J ; Nunez, D J R ; Schneider, B ; Wang, M‐D ; Chen, Y ; Ghosh, S ; Musser, B J ; Vassileva, M T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3727-95e36ca80915ff98fa0b6b8f080efc5360db7108893b169da6259f9beecc66353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - metabolism</topic><topic>Cooperative Behavior</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Delivery Systems - trends</topic><topic>Drug Design</topic><topic>Drug Industry - economics</topic><topic>Drug Industry - methods</topic><topic>Drug Industry - trends</topic><topic>Economic Competition - economics</topic><topic>Economic Competition - trends</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, J A</creatorcontrib><creatorcontrib>Prince, M</creatorcontrib><creatorcontrib>Wright, E C</creatorcontrib><creatorcontrib>Ennis, M M</creatorcontrib><creatorcontrib>Kochan, J</creatorcontrib><creatorcontrib>Nunez, D J R</creatorcontrib><creatorcontrib>Schneider, B</creatorcontrib><creatorcontrib>Wang, M‐D</creatorcontrib><creatorcontrib>Chen, Y</creatorcontrib><creatorcontrib>Ghosh, S</creatorcontrib><creatorcontrib>Musser, B J</creatorcontrib><creatorcontrib>Vassileva, M T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, J A</au><au>Prince, M</au><au>Wright, E C</au><au>Ennis, M M</au><au>Kochan, J</au><au>Nunez, D J R</au><au>Schneider, B</au><au>Wang, M‐D</au><au>Chen, Y</au><au>Ghosh, S</au><au>Musser, B J</au><au>Vassileva, M T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2010-05</date><risdate>2010</risdate><volume>87</volume><issue>5</issue><spage>539</spage><epage>542</epage><pages>539-542</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public–private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator–activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross‐company precompetitive collaboration is a feasible robust approach to biomarker qualification.
Clinical Pharmacology & Therapeutics (2010) 87 5, 539–542. doi: 10.1038/clpt.2009.227</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>20407460</pmid><doi>10.1038/clpt.2009.227</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2010-05, Vol.87 (5), p.539-542 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733592570 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Biological and medical sciences Biomarkers - metabolism Cooperative Behavior Drug Delivery Systems - methods Drug Delivery Systems - trends Drug Design Drug Industry - economics Drug Industry - methods Drug Industry - trends Economic Competition - economics Economic Competition - trends Humans Medical sciences Pharmacology. Drug treatments Randomized Controlled Trials as Topic - trends |
| title | The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A44%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Biomarkers%20Consortium:%20Practice%20and%20Pitfalls%20of%20Open%E2%80%90Source%20Precompetitive%20Collaboration&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Wagner,%20J%20A&rft.date=2010-05&rft.volume=87&rft.issue=5&rft.spage=539&rft.epage=542&rft.pages=539-542&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2009.227&rft_dat=%3Cproquest_cross%3E733592570%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733592570&rft_id=info:pmid/20407460&rfr_iscdi=true |